For the quarter ending 2025-09-30, SNSE had -$1,995K decrease in cash & cash equivalents over the period. -$3,586K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -4,568 | -11,800 |
| Stock-based compensation expense | 254 | 725 |
| Depreciation and amortization | 30 | 62 |
| Accretion on marketable securities | -142 | -442 |
| Non-cash lease expense | 366 | 770 |
| Amortization of financing lease right-of-use assets | 4 | 9 |
| Loss on asset disposal | -1 | -20 |
| Prepaid expenses | -331 | 354 |
| Other assets | 126 | -28 |
| Accounts payable and accrued liabilities | 269 | -113 |
| Compensation and employee benefits | 381 | -1,107 |
| Operating lease liabilities | -386 | -801 |
| Other liabilities | 0 | - |
| Net cash used in operating activities | -3,586 | -13,003 |
| Purchases of property and equipment | 0 | 16 |
| Purchases of short-term investments | 9,847 | 8,786 |
| Maturities of short-term investments | 11,590 | 24,500 |
| Proceeds from sale of property and equipment | 0 | 250 |
| Net cash provided by investing activities | 1,743 | 15,948 |
| Principal payments for financing leases | 152 | 525 |
| Proceeds from the sale of financing lease assets | 0 | 142 |
| Payment of employee restricted stock tax withholdings | 0 | 3 |
| Employee stock purchase plan proceeds | 0 | 5 |
| Cash in lieu of fractional shares for reverse stock split | 0 | 1 |
| Net cash used in financing activities | -152 | -382 |
| Net increase in cash and cash equivalents | -1,995 | 2,563 |
| Cash and cash equivalents at beginning of period | 9,994 | - |
| Cash and cash equivalents at end of period | 10,562 | - |
Sensei Biotherapeutics, Inc. (SNSE)
Sensei Biotherapeutics, Inc. (SNSE)